Injectable formulations containing ramoplanin

A pharmaceutical formulation for intravenous administration which comprises ramoplanin or a member of the ramoplanin family of formula I

• Wherein:
• R represents —CO—CH═CH—CH═CH—CH2—CH2—CH3,
• —CO—CH═CH—CH═CH—CH2—CH (CH3)2,
• —CO—CH═CH—CH═CH—CH2—CH2—CH (CH3)2,
• —CO—CH2—CH2—CH2—CH2—CH2—CH2—CH3,
• —CO—CH2—CH2—CH2—CH2—CH2—CH (CH3)2 or
• —CO—CH2—CH2—CH2—CH2—CH2—CH2—CH (CH3)2
• R′ represents alpha-D-mannopyranosyl or 2-O-alpha-D-mannopyranosyl-alpha-D-mannopyranosil, or
• R′ represents 2,3-O-di[alpha-D-mannopyranosyl]-D-mannopyranosyl when R represents —CO—CH═CH—CH═CH—CH2—CH(CH3)2,
• a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof in any proportion, in admixture with an amount of fat emulsion product for intravenous administration being a lipid in water microemulsion suitable to be administered by the parental route comprising an oil phase, an emulsifier, and at least one additive as an osmotic agent wherein the concentration of the oil phase is from 0.2% to 40% (weight/vol) in the final intravenous formulation and comprises at least one vegetal oil consisting of soybean oil, cottonseed oil and sunflower oil which are partially or totally substituted with a mixture of long chain fatty acids in the form of triglycerides having a percent (wt/wt) composition substantially similar to that of the vegetal oil, and the emulsifier is based on at least one phospholipid.